PositiveID Corporation announced today that it has filed a provisional patent application with the U.S. Patent and Trademark Office for an insulin pen tracking and recording device. The Insulin Tracker, a microprocessor-controlled device that slides onto standard insulin pens, enables diabetes patients to automatically track and record the amount of insulin they inject, including the time and date of each injection. The data is communicated from the Insulin Tracker’s memory, along with the patient’s blood glucose readings from their glucometer, to the iGlucose System database. The combined data provides a more complete record of blood glucose measurements, treatments and overall diabetes management and allows patients, caregivers and physicians to monitor compliance.
Insulin pens provide a convenient and accurate alternative to drawing up and measuring individual insulin doses. There are two types of conventional insulin pens: those that are completely disposable after providing a single dose of insulin, and those that use disposable cartridges to provide multiple doses. The Insulin Tracker device will attach to conventional insulin pens and can be removed from one pen and attached to another pen with ease. The device eliminates the need to manually or otherwise record insulin administration data.
PositiveID launched development of the Insulin Tracker during the second quarter of 2010 to complement and expand the functionality of its iGlucose system. The iGlucose system is a stand-alone, self-contained unit that automatically queries a diabetic user’s data-capable glucometer for blood glucose data and sends that data via encrypted SMS text messaging to an online database. The iGlucose system functions without the use of a cell phone, wireless network, telephone line or personal computer. The Insulin Tracker will work seamlessly with the iGlucose system to include a patient’s insulin dosing data, which is a critical component of accurate diabetes management.
